Sun Pharma - Specialty To Drive Future Growth: Nirmal Bang

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Nirmal Bang Report.Sun Pharmaceutical Industries Ltd.'s revenue is expected to grow at ~12% compound annual growth rate over FY23-FY26E, driven by all geographies (excluding U.S. generics business). Domestic growth will mainly be driven by continuous strong growth in the Chronic segment. Global Specialty segment revenue is expected to clock ~14% CAGR over FY23-FY26E mainly on the back of persistent ramp-up in Winlevi and Ilumya, which will partially be offset by heightened generic competition in Absorica. Rest of world/emerging market markets are expected to grow at 33%/11% CAGR over FY23-FY26E. Ebitda margin is expected to remain healthy at ~27%. Net profit is expected to grow at ~16% CAGR over FY23-FY26E mainly on the back of a strong operational performance..The stock is currently trading at 32.7 times/27.3 times PE on FY25E/FY26E and 23.2 times/19.7 times enterprise value/Ebitda on FY25E/FY26E. Retrun on equity/return on capital employed is expected to remain decent at 17.7%/16% in FY26E. Free cash flow generation is expected to remain strong at more than Rs 200 billion over FY24E-FY26E. .We remain positive about Sun Pharma on a long-term basis due to the following catalysts:Ramp-up of branded/specialty business in the U.S.,Continued growth in India business,Potential inorganic opportunity given the strong balance sheet, Maintenance of healthy Ebitda margin at ~25%. .However, additional costs and revenue loss due to the Halol import alert and Mohali plant issues are likely to be near-term concerns for Sun Pharma. Additionally, increase in research and development costs, other expenses and reduced topline growth are key concerns. We are structurally positive about the company and maintain Acumulate with a target price of Rs 1,579, valuing it at 28 times FY26E earnings per share of Rs 56.40..Click on the attachment to read the full report:.Ambuja Cements - Announced Acqusition Of Penna Cement: Motilal Oswal.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sun Pharma - Specialty To Drive Future Growth: Nirmal Bang

FY24 revenue increased by 10.4% to Rs 477,585 million, with improved gross margin and a rise in market share from 8.3% to 8.5%.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Sun Pharma - Specialty To Drive Future Growth: Nirmal Bang

FY24 revenue increased by 10.4% to Rs 477,585 million, with improved gross margin and a rise in market share from 8.3% to 8.5%.

Choose a plan

Follow Us

DOWNLOAD THE APP